Introduction
============

Migraine is one of the most prevalent and disabling chronic conditions globally, which exerts significant burdens on individuals and the society [@R1]. However, the underlying pathological mechanisms remain poorly understood. It is thus very important to investigate the clinical characteristics of migraine and to identify potential biomarkers, which will benefit the diagnosis and treatment of migraine.

γ-Aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system [@R2] and may serve as a possible biomarker for migraine. It is distributed widely in the brain and has been implicated in the temporal modulation of neuronal excitability and neuronal disorders, such as pain [@R3]. As an important regulator of excitation and inhibition [@R4], the change in brain GABA levels could result in pathophysiological events leading to migraine [@R5]. Therefore, it is important to study the GABA levels in migraine to gain an understanding of the pathogenesis of migraine.

Levetiracetam (LEV) is a new antiepileptic drug (AED). It can inhibit high-voltage-gated N-type Ca^2+^ channel current, Zn^2+^-associated negative modulation of GABA, and GABA release [@R6]. In addition to epilepsy, LEV may also be effective in treating migraine according to some small open-label trials [@R7]--[@R9]. However, to the best of our knowledge, there has been no report on the alterations in intracerebral GABA+ levels in patients with migraine after LEV treatment.

Patients and methods
====================

Patients
--------

Patients who were diagnosed with migraine by the Headache Specific Outpatients of Shandong Provincial Hospital were followed up between March 2016 and September 2016. This research was approved by the Human Research Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University (no. 2017-213). All participants provided written informed consent.

The patients fulfilled the International Classification of Headache Disorders-III criteria for migraine and had at least one migraine attack per month identified by the attending neurologist/physician. Exclusion criteria included nonmigrainous headaches according to International Classification of Headache Disorders-III criteria, a history of neck injury, claustrophobia or severe depression (i.e. Depression Anxiety Stress Scales-21 score of \>21), pregnancy, presence of conditions that would compromise spectroscopy data (e.g. implants, tattoo, dental braces), or use of medications known to alter GABA levels.

Methods
-------

Participants with migraine provided information on headache characteristics including history of migraine, headache frequency (attacks per month), typical duration of each migraine episode, and headache intensity in the past month using the visual analogue scale (with anchors at 0 and 10: 0=no pain, 10=worst pain possible). After participants underwent initial proton magnetic resonance spectroscopy (^1^H-MRS), LEV was initiated at 250 mg/day for the first week and incremented to a total dose of 500 mg/day (250 mg, twice daily) after 1 week. Following 12 weeks of treatment, ^1^H-MRS was repeated. During LEV therapy, patients stopped using other medications, except ibuprofen. Headache frequency and intensity were recorded at baseline and after 12 weeks of treatment.

Proton magnetic resonance spectroscopy
--------------------------------------

Scans were performed on an Achieva 3.0-T TX scanner equipped with an eight-channel phased-array head coil (Philips Healthcare, Best, The Netherlands). Before examination, T1-weighted 3D turbo field echo images were used for localization and the scanning parameters were set as follows: TR=8.1 ms; TE=3.7 ms; slice thickness=1 mm; matrix: 256×256; field of view=24×24 cm^2^; and flip angle=8°. The MRS voxels (volume size 3×3×3 cm^3^ and 3×2×3 cm^3^) were set on the anterior cingulate cortex/medial prefrontal cortex (ACC/mPFC) and the posterior cingulate cortex (PCC) (Fig. [1](#F1){ref-type="fig"}). The median sagittal plane was selected as a reference slice for voxel localization. The ACC/mPFC is the frontal part of the cingulate cortex that resembles a 'collar' surrounding the frontal part of the corpus callosum. The PCC is the caudal part of the cingulate cortex, located posterior to the ACC. All of the MRS voxels were positioned in such a manner as to avoid the lateral ventricle and skull.

![Magnetic resonance spectroscopy voxel placement and resulting spectra. T1-weighted turbo field echo (TFE) images show single-voxel placements centered on the anterior cingulated cortex/median prefrontal cortex (ACC/mPFC) in the sagittal (a), axial (b) projections and on the posterior cingulated cortex (PCC) in the sagittal (d), axial (e) projections. Representative spectra were obtained from the ACC/mPFC (c) and the PCC (f) using the MEGA-PRESS sequence. γ-Aminobutyric acid (GABA) was resolved at 3.02 ppm.](wnr-29-1007-g001){#F1}

We quantified GABA using the MEGA-PRESS method [@R10] with the following parameters: TR=2000 ms; TE=68 ms; 320 signal averages; acquisition bandwidth=1000 Hz; and scan duration 8 min 48 s. J-evolution for GABA was refocused during odd-numbered acquisitions (ON), but not during even numbered acquisitions (OFF) by applying a Gaussian inversion pulse to the 3CH2 resonance of GABA at 1.9 ppm (ON) and at 7.5 ppm symmetrically about the water peak (OFF), respectively. Water suppression was carried out using chemical shift-selective pulses after automatic optimization. FASTMAP shimming of the volume-of-interest was performed automatically before each acquisition. Eight averages of the unsuppressed water signal were obtained for quantification. The difference between 'ON' and 'OFF' spectra provided an edited spectrum of GABA. As the measured GABA signal at 3.02 ppm is also likely to contain a contribution from co-edited macromolecules and homocarnosine resonances [@R11], therefore, we will refer to the GABA signals as GABA+.

Statistical analysis
--------------------

The baseline GABA+ levels and clinical data were compared with comparative data after 12-week LEV monotherapy using a paired-samples *t*-test. Statistical significance was defined as *P* value of less than 0.05. Statistical analysis was carried out using the SPSS 19.0 software package (IBM Corp., Armonk, New York, USA).

T1-weighted turbo field echo images show single-voxel placements centered on the ACC/mPFC in the sagittal (a), axial (b) projections and on the PCC in the sagittal (d), axial (e) projections. Representative spectra were obtained from the ACC/mPFC (c) and the PCC (f) using the MEGA-PRESS sequence.GABA is resolved at 3.02 ppm.

Results
=======

Clinical results
----------------

Twenty-five patients were recruited into the study. Eleven patients dropped out, either lost to follow-up, withdrew from the study, or did not adhere to medication. Finally, 14 patients with migraine were analyzed in this study. These migraine patients were between 15 and 60 years of age (mean, 40.19 years) and 12 patients were females. Patients had experienced migraine for a duration of between 3 and 30 years (mean, 12.21 years). There was one migraine patient with aura and 13 migraine patients without aura in the research. Patients treated with LEV showed a significant decrease in headache frequency and intensity compared with pretreatment (Table [1](#T1){ref-type="table"}).
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Results of proton magnetic resonance spectroscopy
-------------------------------------------------

There were 14 patients who underwent MRS re-examination after 12 weeks of LEV therapy. For eleven of these patients, good-quality spectral data of GABA+ in PCC were obtained. Eight of these patients showed good-quality spectral results of GABA+ in ACC/mPFC. Neurotransmitter results from ^1^H-MRS are shown in Table [2](#T2){ref-type="table"}.
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Discussion
==========

Here, we found a significant decrease in PCC GABA+ levels in patients with migraine responding to LEV monotherapy (*P*=0.015). This finding suggests an indirect influence of LEV on the GABAergic system and a potential biomarker role of GABA in migraine treatment.

The underlying pathophysiology of migraine remains incompletely defined, but it most likely involves complex mechanisms of the peripheral nervous system and the central nervous system. To date, no robust biomarkers have been identified for migraine, but many studies have suggested cerebral dysfunction in migraine patients, most notably including altered excitability of the brain, as well as abnormal levels of the neurotransmitters glutamate and GABA in the occipital cortex and the cingulate cortex, which are involved in pain processing [@R12]--[@R16].

GABA is one of the possible biomarkers for migraine. Given the inhibitory function of GABA in most brain synapses, including its involvement in vasodilatation, GABA has been implicated in the pathophysiology of migraine [@R17]--[@R20]. It has been reported that patients had higher GABA levels in the cerebrospinal fluid during a migraine attack than those during the headache-free period [@R21]. GABA levels were also found to be higher in the blood platelet of patients with tension headache [@R22]. Recently, GABA was shown to cause vasodilation during the interaction with neurons, blood vessels, and astrocytes during cortical spreading depression and the trigeminovascular system activation [@R23]--[@R25].

LEV is a new AED, and its mechanism of action is not fully understood. Synaptic vesicle protein 2A has been identified as the binding site of LEV in the brain, suggesting a novel mechanism of action distinct from that of other AEDs. LEV can inhibit high-voltage-gated N-type Ca^2+^ channel current, Zn^2+^-associated negative modulation of GABA, and GABA release [@R6]. GABA-mediated inhibition is involved in the pathophysiological events underlying migraine and may represent a target for AEDs in migraine treatment. Our results showed a good efficacy of LEV -- a novel AED, in the reduction of migraine frequency and intensity in patients with migraine. We successfully obtained the PCC GABA+ levels by ^1^H-MRS in 11 patients with migraine. Accordingly, a significant decrease in GABA+ levels was found in the PCC region of these patients. Indeed, increased GABA concentration in the human cerebral cortex has been noted during painful stimulation [@R3]. In addition, PCC GABA+ levels were elevated in migraine during the interictal period [@R15]. Thus, the association between the decreased GABA+ levels and the clinical benefits of LEV treatment indicates a change in brain chemistry specific to migraine. These results together support a putative role for GABA in migraine pathophysiology. There might exist an indirect influence of LEV on the GABAergic system in patients with migraine, which warrants further studies to validate GABA as a migraine biomarker. It is speculated that the brain GABA levels decrease with the alleviation of migraine pain.

There are some limitations of the present study that should be noted. First, GABA+ was measured in single-voxel areas of the ACC/mPFC and PCC regions. It was not clear whether the changes in GABA+ levels were different in other regions. Second, spectroscopy was performed only during the interictal period. Additional spectroscopic studies during the ictal period are needed. Nevertheless, our current data have shown the decrease in GABA+ levels associated with effective treatment, shedding light on novel treatment strategies and clinical outcome.

Conclusion
==========

LEV showed good efficacy in the reduction of headache frequency and intensity in patients with migraine and was associated with a significant decrease in GABA+ levels in the PCC region. Further study is warranted to validate GABA as a migraine biomarker.
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